Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
6
Neutral
5
Bullish
3
Bearish
6
Neutral
5
Bullish
35
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Aurobindo Pharma Limited is a global pharmaceutical company that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, injectables and a growing biosimilars portfolio across regulated and growth markets, operating multiple manufacturing sites and R&D centres to serve over 150 countries with a broad ANDA/DMF filing base and expanding biologics capabilities.
Q3FY26 consolidated revenue reached Rs. 8,646 crore, up 8.4% YoY, with EBITDA of Rs. 1,773 crore (20.5% margin) and net profit of Rs. 910 crore; management highlighted stable US base business, strong European growth (+27% YoY) and R&D spend of Rs. 409 crore (4.7% of sales) focused on biosimilars and specialty products development.
Biosimilars (CuraTeQ) are a strategic growth pillar: multiple 2025 approvals in EEA/UK/Canada, filings planned in EMA and Health Canada, two Phase‑3 programs ongoing and planned US/EU BLA/MAA engagement for denosumab and omalizumab in 2026, positioning Aurobindo for a biotech revenue inflection toward 2028–2029.
Operationally, Aurobindo reported meaningful capex and cash generation: net capex of US$79mn in the quarter, free cash flow generation of US$118mn and a strong net cash position (~US$251mn after appropriations), enabling both organic capacity build and selective M&A such as the Lannett transaction under regulatory review.
Key near‑term drivers include: commercialization momentum in Europe, ramp of Pen‑G/6‑APA capacity with Govt MIP support, continued ANDA approvals and product launches in the US, and biosimilars commercialization and filings that together create multi‑year earnings visibility across segments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
87,861 Cr
Low Risk
25.2
35.0
1.1
2.5
1,459.75
1,017.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockAurobindo Pharma Ltd (AUROPHARMA) is currently trading at 1,518.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aurobindo Pharma Limited is a global pharmaceutical company that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, injectables and a growing biosimilars portfolio across regulated and growth markets, operating multiple manufacturing sites and R&D centres to serve over 150 countries with a broad ANDA/DMF filing base and expanding biologics capabilities. Q3FY26 consolidated revenue reached Rs. 8,646 crore, up 8.4% YoY, with EBITDA of Rs. 1,773 crore (20.5% margin) and net profit of Rs. 910 crore; management highlighted stable US base business, strong European growth (+27% YoY) and R&D spend of Rs. 409 crore (4.7% of sales) focused on biosimilars and specialty products development. Biosimilars (CuraTeQ) are a strategic growth pillar: multiple 2025 approvals in EEA/UK/Canada, filings planned in EMA and Health Canada, two Phase‑3 programs ongoing and planned US/EU BLA/MAA engagement for denosumab and omalizumab in 2026, positioning Aurobindo for a biotech revenue inflection toward 2028–2029. Operationally, Aurobindo reported meaningful capex and cash generation: net capex of US$79mn in the quarter, free cash flow generation of US$118mn and a strong net cash position (~US$251mn after appropriations), enabling both organic capacity build and selective M&A such as the Lannett transaction under regulatory review. Key near‑term drivers include: commercialization momentum in Europe, ramp of Pen‑G/6‑APA capacity with Govt MIP support, continued ANDA approvals and product launches in the US, and biosimilars commercialization and filings that together create multi‑year earnings visibility across segments.
Over the past 52 weeks, Aurobindo Pharma Ltd has traded between a low of ₹1,017.00 and a high of ₹1,459.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aurobindo Pharma Ltd has a market capitalization of approximately 87,860.77. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aurobindo Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 87,860.77 Cr, Aurobindo Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aurobindo Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd is 25.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
A broad rally in pharma stocks, several 52-week highs, and the rupee’s record low supported sentiment, as exporters benefit from higher rupee value of dollar revenues.
An NOC is issued after a successful review and grants formal marketing authorisation, confirming the biosimilar meets regulatory standards for safety, efficacy, and quality.
Aurobindo said its subsidiary Eugia Pharma Specialities received the final USFDA approval to manufacture and market Dasatinib Tablets.
The stock moved up after the USFDA issued an EIR classifying Apitoria Pharma’s Telangana Unit-V as VAI, indicating the inspection was closed without regulatory or enforcement action.
Regulatory Order
Aurobindo Pharma informs that the Hon'ble High Court of Telangana on May 6, 2026 dismissed promoters' writ challenging SEBI's direction to deposit Rs.6.53 crore profits plus interest under a settlement; company states no financial impact.
Regulatory Approval
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, received CDSCO Marketing Authorization (Form CT 23) for Bevqolva® (bevacizumab biosimilar) for metastatic colorectal cancer, permitting manufacture in Hyderabad and marketing in 100 mg/4 mL and 400 mg/16 mL vials.
Buyback Extinguishment
Aurobindo Pharma extinguished 5,423,728 equity shares (face value Re.1) bought back at ₹1,475/share (aggregate ~₹800 crore), reducing issued capital from 580,801,623 to 575,377,895 shares; NSDL/CDSL certificates enclosed.
Earnings Call Invite
Aurobindo Pharma will host an earnings call on May 22, 2026 at 8:30 AM IST to discuss audited financial results for the fourth quarter and year ended March 31, 2026; presentation to be posted on the company's website.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2326.80 | 1,04,542 Cr | 19.60 | 4.66 | 0.79 | 23.76 | 24.88 | 13.96 | ||
2507.00 | 1,02,964 Cr | 57.87 | 6.74 | 0.00 | 11.45 | 12.34 | 6.26 | ||
864.25 | 1,02,530 Cr | 20.76 | 4.05 | 0.10 | 19.44 | 19.08 | 10.52 | ||
1415.00 | 87,861 Cr | 25.20 | 2.51 | 0.00 | 9.77 | 12.69 | 6.63 | ||
1129.60 | 72,611 Cr | 81.70 | 13.70 | 0.09 | 16.77 | 16.14 | 8.47 | ||
350.55 | 69,367 Cr | 179.89 | 2.04 | 0.12 | 1.14 | 3.64 | 0.58 | ||
2161.50 | 67,876 Cr | 63.73 | 7.08 | 0.10 | 26.24 | 30.84 | 5.60 | ||
| Median: 7 Co. | — | 1415.00 | 87,861 Cr | 57.87 | 4.66 | 0.10 | 16.77 | 16.14 | 6.63 |
